{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:30:15Z","timestamp":1791387015630,"version":"4.3.3"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T00:00:00Z","timestamp":1517875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created\u00a0through chemical modification to improve treatment outcomes. A hydrophobic and lipophilic modified DTG prodrug is encapsulated into poloxamer nanoformulations (NMDTG) and characterized by size, shape, polydispersity, and stability. Retained intracytoplasmic NMDTG particles release drug from macrophages and attenuate viral replication and spread of virus to CD4+ T cells. Pharmacokinetic tests in Balb\/cJ mice show blood DTG levels at, or above, its inhibitory concentration<jats:sub>90<\/jats:sub>of 64\u2009ng\/mL for 56 days, and tissue DTG levels for 28 days. NMDTG protects humanized mice from parenteral challenge of the\u00a0HIV-1<jats:sub>ADA<\/jats:sub>strain for two weeks. These results are a first step towards producing a long-acting DTG for human use by\u00a0affecting drug apparent half-life, cell and tissue drug penetration, and antiretroviral\u00a0potency.<\/jats:p>","DOI":"10.1038\/s41467-018-02885-x","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T23:25:31Z","timestamp":1516836331000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Creation of a long-acting nanoformulated dolutegravir"],"prefix":"10.1038","volume":"9","author":[{"given":"Brady","family":"Sillman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya N.","family":"Bade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasanta K.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biju","family":"Bhargavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saumi","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgette D.","family":"Kanmogne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa Y.","family":"Poluektova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoEllyn","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagsen","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazen","family":"Alnouti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benson","family":"Edagwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard E.","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"2885_CR1","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.lpm.2017.01.017","volume":"46","author":"S Tiberi","year":"2017","unstructured":"Tiberi, S. et al. The cursed duet today: tuberculosis and HIV-coinfection. Presse Med. 46, e23\u2013e39 (2017).","journal-title":"Presse Med."},{"key":"2885_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.7861\/clinmedicine.8-5-539","volume":"8","author":"EL Ong","year":"2008","unstructured":"Ong, E. L. Common AIDS-associated opportunistic infections. Clin. Med. 8, 539\u2013543 (2008).","journal-title":"Clin. Med."},{"key":"2885_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0738-3991(01)00219-1","volume":"46","author":"L Fogarty","year":"2002","unstructured":"Fogarty, L. et al. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ. Couns. 46, 93\u2013108 (2002).","journal-title":"Patient Educ. Couns."},{"key":"2885_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.antiviral.2009.10.007","volume":"85","author":"JA Este","year":"2010","unstructured":"Este, J. A. & Cihlar, T. Current status and challenges of antiretroviral research and therapy. Antivir. Res. 85, 25\u201333 (2010).","journal-title":"Antivir. Res."},{"key":"2885_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nm0414-323","volume":"20","author":"E Dolgin","year":"2014","unstructured":"Dolgin, E. Long-acting HIV drugs advanced to overcome adherence challenge. Nat. Med. 20, 323\u2013324 (2014).","journal-title":"Nat. Med."},{"key":"2885_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11904-017-0353-0","volume":"14","author":"AN Nyaku","year":"2017","unstructured":"Nyaku, A. N., Kelly, S. G. & Taiwo, B. O. Long-acting antiretrovirals: where are we now? Curr. HIV\/AIDS Rep. 14, 63\u201371 (2017).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"2885_CR7","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/nrd1494","volume":"3","author":"BE Rabinow","year":"2004","unstructured":"Rabinow, B. E. Nanosuspensions in drug delivery. Nat. Rev. Drug. Discov. 3, 785\u2013796 (2004).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"2885_CR8","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/138920006775541552","volume":"7","author":"SS Singh","year":"2006","unstructured":"Singh, S. S. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr. Drug. Metab. 7, 165\u2013182 (2006).","journal-title":"Curr. Drug. Metab."},{"key":"2885_CR9","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1208\/s12248-015-9814-9","volume":"17","author":"H Wen","year":"2015","unstructured":"Wen, H., Jung, H. & Li, X. Drug delivery approaches in addressing clinical pharmacology-related issues: opportunities and challenges. AAPS J. 17, 1327\u20131340 (2015).","journal-title":"AAPS J."},{"key":"2885_CR10","doi-asserted-by":"publisher","first-page":"e331","DOI":"10.1016\/S2352-3018(17)30068-1","volume":"4","author":"M Markowitz","year":"2017","unstructured":"Markowitz, M. et al. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. Lancet HIV 4, e331\u2013e340 (2017).","journal-title":"Lancet HIV"},{"key":"2885_CR11","doi-asserted-by":"publisher","unstructured":"Chamanza, R., Darville, N., van Heerden, M. & De Jonghe, S. Comparison of the local tolerability to 5 long-acting drug nanosuspensions with different stabilizing excipients, following a single intramuscular administration in the rat. Toxicol. Pathol. https:\/\/doi.org\/10.1177\/0192623317737295 (2017).","DOI":"10.1177\/0192623317737295"},{"key":"2885_CR12","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1097\/QAI.0000000000001170","volume":"74","author":"D Guo","year":"2017","unstructured":"Guo, D. et al. Creation of a long-acting nanoformulated 2\u2019,3\u2019-dideoxy-3\u2019-thiacytidine. J. Acquir. Immune Defic. Syndr. 74, e75\u2013e83 (2017).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"2885_CR13","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.2217\/nnm-2016-0164","volume":"11","author":"D Singh","year":"2016","unstructured":"Singh, D. et al. Development and characterization of a long-acting nanoformulated abacavir prodrug. Nanomedicine 11, 1913\u20131927 (2016).","journal-title":"Nanomedicine"},{"key":"2885_CR14","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi, M. et al. In vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55, 813\u2013821 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2885_CR15","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1002\/jps.20542","volume":"95","author":"BM Liederer","year":"2006","unstructured":"Liederer, B. M. & Borchardt, R. T. Enzymes involved in the bioconversion of ester-based prodrugs. J. Pharm. Sci. 95, 1177\u20131195 (2006).","journal-title":"J. Pharm. Sci."},{"key":"2885_CR16","first-page":"3393","volume":"6","author":"S Balkundi","year":"2011","unstructured":"Balkundi, S. et al. Comparative manufacture and cell-based delivery of antiretroviral nanoformulations. Int. J. Nanomed. 6, 3393\u20133404 (2011).","journal-title":"Int. J. Nanomed."},{"key":"2885_CR17","doi-asserted-by":"publisher","first-page":"e10051","DOI":"10.1371\/journal.pone.0010051","volume":"5","author":"N Doshi","year":"2010","unstructured":"Doshi, N. & Mitragotri, S. Macrophages recognize size and shape of their targets. PLoS ONE 5, e10051 (2010).","journal-title":"PLoS ONE"},{"key":"2885_CR18","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s10461-011-9942-x","volume":"15","author":"C Ortego","year":"2011","unstructured":"Ortego, C. et al. Adherence to highly active antiretroviral therapy (HAART): a meta-analysis. Aids. Behav. 15, 1381\u20131396 (2011).","journal-title":"Aids. Behav."},{"key":"2885_CR19","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(09)70227-0","volume":"9","author":"JA Bartlett","year":"2009","unstructured":"Bartlett, J. A. & Shao, J. F. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect. Dis. 9, 637\u2013649 (2009).","journal-title":"Lancet Infect. Dis."},{"key":"2885_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2014.03.053","volume":"190","author":"AC Anselmo","year":"2014","unstructured":"Anselmo, A. C. & Mitragotri, S. An overview of clinical and commercial impact of drug delivery systems. J. Control. Release 190, 15\u201328 (2014).","journal-title":"J. Control. Release"},{"key":"2885_CR21","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1128\/AAC.03906-14","volume":"59","author":"JM Cortez Jr","year":"2015","unstructured":"Cortez, J. M. Jr et al. Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants. Antimicrob. Agents Chemother. 59, 59\u201366 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2885_CR22","first-page":"7508291","volume":"2017","author":"Q Li","year":"2017","unstructured":"Li, Q. et al. Long-term prophylaxis and pharmacokinetic evaluation of intramuscular Nano- and microparticle decoquinate in mice infected with P. berghei sporozoites. Malar. Res Treat. 2017, 7508291 (2017).","journal-title":"Malar. Res Treat."},{"key":"2885_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/bit.21301","volume":"96","author":"DS Kohane","year":"2007","unstructured":"Kohane, D. S. Microparticles and nanoparticles for drug delivery. Biotechnol. Bioeng. 96, 203\u2013209 (2007).","journal-title":"Biotechnol. Bioeng."},{"key":"2885_CR24","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.drudis.2013.08.014","volume":"19","author":"SD Clas","year":"2014","unstructured":"Clas, S. D., Sanchez, R. I. & Nofsinger, R. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges. Drug Discov. Today 19, 79\u201387 (2014).","journal-title":"Drug Discov. Today"},{"key":"2885_CR25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s12272-013-0105-7","volume":"36","author":"EJ Park","year":"2013","unstructured":"Park, E. J. et al. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Arch. Pharm. Res. 36, 651\u2013659 (2013).","journal-title":"Arch. Pharm. Res."},{"key":"2885_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1172\/JCI90025","volume":"127","author":"DP Gnanadhas","year":"2017","unstructured":"Gnanadhas, D. P. et al. Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs. J. Clin. Invest. 127, 857\u2013873 (2017).","journal-title":"J. Clin. Invest."},{"key":"2885_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.virol.2012.10.007","volume":"435","author":"R Akkina","year":"2013","unstructured":"Akkina, R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 435, 14\u201328 (2013).","journal-title":"Virology"},{"key":"2885_CR28","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1093\/jac\/dkx195","volume":"72","author":"A Heredia","year":"2017","unstructured":"Heredia, A. et al. Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice. J. Antimicrob. Chemother. 72, 2570\u20132573 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"2885_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-60761-058-8_7","volume":"602","author":"S Pino","year":"2010","unstructured":"Pino, S. et al. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol. Biol. 602, 105\u2013117 (2010).","journal-title":"Methods Mol. Biol."},{"key":"2885_CR30","doi-asserted-by":"publisher","first-page":"e547","DOI":"10.1016\/S2352-3018(17)30152-2","volume":"4","author":"I Wijting","year":"2017","unstructured":"Wijting, I. et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV 4, e547\u2013e554 (2017).","journal-title":"Lancet HIV"},{"key":"2885_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/blood-2006-04-017681","volume":"109","author":"S Watanabe","year":"2007","unstructured":"Watanabe, S. et al. Hematopoietic stem cell-engrafted NOD\/SCID\/IL2R gamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 109, 212\u2013218 (2007).","journal-title":"Blood"},{"key":"2885_CR32","doi-asserted-by":"publisher","first-page":"e522","DOI":"10.1016\/S2352-3018(17)30132-7","volume":"4","author":"E Hoornenborg","year":"2017","unstructured":"Hoornenborg, E. et al. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Lancet HIV 4, e522\u2013e528 (2017).","journal-title":"Lancet HIV"},{"key":"2885_CR33","doi-asserted-by":"publisher","first-page":"e01316","DOI":"10.1128\/AAC.01316-17","volume":"62","author":"J McMillan","year":"2017","unstructured":"McMillan, J. et al. Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob. Agents Chemother. 62, e01316\u2013e01317 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2885_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17425247.2017.1288212","volume":"14","author":"B Edagwa","year":"2017","unstructured":"Edagwa, B., McMillan, J., Sillman, B. & Gendelman, H. E. Long-acting slow effective release antiretroviral therapy. Expert Opin. Drug Deliv. 14, 1\u201311 (2017).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2885_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S1773-2247(09)50001-9","volume":"19","author":"MS Palombo","year":"2009","unstructured":"Palombo, M. S., Singh, Y. & Sinko, P. J. Prodrug and conjugate drug delivery strategies for improving HIV\/AIDS therapy. J. Drug Deliv. Sci. Technol. 19, 3\u201314 (2009).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"2885_CR36","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood-2006-03-012534","volume":"108","author":"H Dou","year":"2006","unstructured":"Dou, H. et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108, 2827\u20132835 (2006).","journal-title":"Blood"},{"key":"2885_CR37","doi-asserted-by":"publisher","first-page":"545","DOI":"10.2217\/nnm.16.1","volume":"11","author":"J Shao","year":"2016","unstructured":"Shao, J. et al. Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV\/AIDS. Nanomedicine 11, 545\u2013564 (2016).","journal-title":"Nanomedicine"},{"key":"2885_CR38","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1089\/aid.2014.0210","volume":"31","author":"JP Freeling","year":"2015","unstructured":"Freeling, J. P., Koehn, J., Shu, C., Sun, J. & Ho, R. J. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res. Hum. Retrovir. 31, 107\u2013114 (2015).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"2885_CR39","doi-asserted-by":"publisher","first-page":"e0145966","DOI":"10.1371\/journal.pone.0145966","volume":"10","author":"AL Martinez-Skinner","year":"2015","unstructured":"Martinez-Skinner, A. L. et al. Cellular responses and tissue depots for nanoformulated antiretroviral therapy. PLoS ONE 10, e0145966 (2015).","journal-title":"PLoS ONE"},{"key":"2885_CR40","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1128\/AAC.00267-13","volume":"57","author":"N Gautam","year":"2013","unstructured":"Gautam, N. et al. Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy. Antimicrob. Agents Chemother. 57, 3110\u20133120 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2885_CR41","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1517\/17425247.2011.559457","volume":"8","author":"EV Batrakova","year":"2011","unstructured":"Batrakova, E. V., Gendelman, H. E. & Kabanov, A. V. Cell-mediated drug delivery. Expert Opin. Drug Deliv. 8, 415\u2013433 (2011).","journal-title":"Expert Opin. Drug Deliv."},{"key":"2885_CR42","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/B978-0-12-416020-0.00014-0","volume":"104","author":"J McMillan","year":"2011","unstructured":"McMillan, J., Batrakova, E. & Gendelman, H. E. Cell delivery of therapeutic nanoparticles. Prog. Mol. Biol. Transl. Sci. 104, 563\u2013601 (2011).","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"2885_CR43","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2217\/nnm.11.27","volume":"6","author":"I Kadiu","year":"2011","unstructured":"Kadiu, I., Nowacek, A., McMillan, J. & Gendelman, H. E. Macrophage endocytic trafficking of antiretroviral nanoparticles. Nanomedicine 6, 975\u2013994 (2011).","journal-title":"Nanomedicine"},{"key":"2885_CR44","doi-asserted-by":"publisher","first-page":"9504","DOI":"10.1128\/JVI.01557-14","volume":"88","author":"D Guo","year":"2014","unstructured":"Guo, D. et al. Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance. J. Virol. 88, 9504\u20139513 (2014).","journal-title":"J. Virol."},{"key":"2885_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-017-0344-7","volume":"14","author":"M Arainga","year":"2017","unstructured":"Arainga, M. et al. A mature macrophage is a principal HIV-1 cellular reservoir in humanized mice after treatment with long acting antiretroviral therapy. Retrovirology 14, 17 (2017).","journal-title":"Retrovirology"},{"key":"2885_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-7-31","volume":"7","author":"A Bergamaschi","year":"2010","unstructured":"Bergamaschi, A. & Pancino, G. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 7, 31 (2010).","journal-title":"Retrovirology"},{"key":"2885_CR47","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","volume":"31","author":"KJ Lepik","year":"2017","unstructured":"Lepik, K. J. et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS 31, 1425\u20131434 (2017).","journal-title":"AIDS"},{"key":"2885_CR48","doi-asserted-by":"publisher","DOI":"10.7448\/IAS.17.4.19518","volume":"17","author":"M Wainberg","year":"2014","unstructured":"Wainberg, M. et al. The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound. J. Int. AIDS Soc. 17, 19518 (2014).","journal-title":"J. Int. AIDS Soc."},{"key":"2885_CR49","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1139\/cjm-2015-0725","volume":"62","author":"MA Wainberg","year":"2016","unstructured":"Wainberg, M. A., Han, Y. S. & Mesplede, T. Might dolutegravir be part of a functional cure for HIV? Can. J. Microbiol. 62, 375\u2013382 (2016).","journal-title":"Can. J. Microbiol."},{"key":"2885_CR50","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/COH.0000000000000219","volume":"11","author":"RJ Landovitz","year":"2016","unstructured":"Landovitz, R. J., Kofron, R. & McCauley, M. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr. Opin. HIV AIDS 11, 122\u2013128 (2016).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2885_CR51","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1097\/QAD.0000000000000280","volume":"28","author":"A Nel","year":"2014","unstructured":"Nel, A. et al. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women. AIDS 28, 1479\u20131487 (2014).","journal-title":"AIDS"},{"key":"2885_CR52","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1128\/AAC.00656-15","volume":"59","author":"M Gunawardana","year":"2015","unstructured":"Gunawardana, M. et al. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob. Agents Chemother. 59, 3913\u20133919 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2885_CR53","unstructured":"Grobler, J. et al. Long-acting oral and parenteral dosing of MK-8591 for HIV treatment or prophylaxis. in Conference on Retroviruses and Opportunistic Infections (Boston, Massachusetts, 2016)."},{"key":"2885_CR54","unstructured":"Chua, C. X. et al. Transcutaneous refillable nanofluidic implant for constant delivery of HIV PrEP. in Conference on Retroviruses and Opportunistic Infections (Seattle, Washington, 2017)."},{"key":"2885_CR55","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s11095-016-1885-5","volume":"33","author":"E Larraneta","year":"2016","unstructured":"Larraneta, E., McCrudden, M. T., Courtenay, A. J. & Donnelly, R. F. Microneedles: a new frontier in nanomedicine delivery. Pharm. Res. 33, 1055\u20131073 (2016).","journal-title":"Pharm. Res."},{"key":"2885_CR56","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2217\/nnm.12.214","volume":"8","author":"J Williams","year":"2013","unstructured":"Williams, J. et al. Long-acting parenteral nanoformulated antiretroviral therapy: interest and attitudes of HIV-infected patients. Nanomedicine 8, 1807\u20131813 (2013).","journal-title":"Nanomedicine"},{"key":"2885_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.biomaterials.2017.10.023","volume":"151","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151, 53\u201365 (2018).","journal-title":"Biomaterials"},{"key":"2885_CR58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.7150\/thno.22764","volume":"8","author":"BD Kevadiya","year":"2018","unstructured":"Kevadiya, B. D. et al. Multimodal theranostic nanoformulations permit magnetic resonance bioimaging of antiretroviral drug particle tissue-cell biodistribution. Theranostics 8, 256\u2013276 (2018).","journal-title":"Theranostics"},{"key":"2885_CR59","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/nnm.09.71","volume":"4","author":"AS Nowacek","year":"2009","unstructured":"Nowacek, A. S. et al. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine 4, 903\u2013917 (2009).","journal-title":"Nanomedicine"},{"key":"2885_CR60","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1084\/jem.167.4.1428","volume":"167","author":"HE Gendelman","year":"1988","unstructured":"Gendelman, H. E. et al. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J. Exp. Med. 167, 1428\u20131441 (1988).","journal-title":"J. Exp. Med."},{"key":"2885_CR61","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1021\/pr400185w","volume":"12","author":"AL Martinez-Skinner","year":"2013","unstructured":"Martinez-Skinner, A. L. et al. Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacity. J. Proteome Res. 12, 2282\u20132294 (2013).","journal-title":"J. Proteome Res."},{"key":"2885_CR62","doi-asserted-by":"crossref","first-page":"298","DOI":"10.4049\/jimmunol.146.1.298","volume":"146","author":"DC Kalter","year":"1991","unstructured":"Kalter, D. C. et al. Enhanced HIV replication in macrophage colony-stimulating factor-treated monocytes. J. Immunol. 146, 298\u2013306 (1991).","journal-title":"J. Immunol."},{"key":"2885_CR63","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11481-010-9198-7","volume":"5","author":"AS Nowacek","year":"2010","unstructured":"Nowacek, A. S. et al. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J. Neuroimmune Pharmacol. 5, 592\u2013601 (2010).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2885_CR64","doi-asserted-by":"publisher","first-page":"7082","DOI":"10.4049\/jimmunol.1000438","volume":"184","author":"S Gorantla","year":"2010","unstructured":"Gorantla, S. et al. CD8+cell depletion accelerates HIV-1 immunopathology in humanized mice. J. Immunol. 184, 7082\u20137091 (2010).","journal-title":"J. Immunol."},{"key":"2885_CR65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.biomaterials.2014.11.012","volume":"41","author":"P Puligujja","year":"2015","unstructured":"Puligujja, P. et al. Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations. Biomaterials 41, 141\u2013150 (2015).","journal-title":"Biomaterials"},{"key":"2885_CR66","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1093\/infdis\/jis395","volume":"206","author":"U Roy","year":"2012","unstructured":"Roy, U. et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J. Infect. Dis. 206, 1577\u20131588 (2012).","journal-title":"J. Infect. Dis."},{"key":"2885_CR67","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1128\/JVI.02010-06","volume":"81","author":"S Gorantla","year":"2007","unstructured":"Gorantla, S. et al. Human immunodeficiency virus type 1 pathobiology studied in humanized BALB\/c-Rag2\u2212\/\u2212gammac\u2212\/\u2212 mice. J. Virol. 81, 2700\u20132712 (2007).","journal-title":"J. Virol."},{"key":"2885_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/srep23513","volume":"6","author":"M Arainga","year":"2016","unstructured":"Arainga, M., Su, H., Poluektova, L. Y., Gorantla, S. & Gendelman, H. E. HIV-1 cellular and tissue replication patterns in infected humanized mice. Sci. Rep. 6, 23513 (2016).","journal-title":"Sci. Rep."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02885-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02885-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02885-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T18:38:27Z","timestamp":1719772707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02885-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["2885"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-02885-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"14 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"443"}}